- Avidity Biosciences, Inc. is a biotechnology company focused on delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), with a market cap of $5.3 billion and a mission to treat serious genetic neuromuscular diseases.
- In October 2025, Avidity announced a definitive merger agreement with Novartis for approximately $12 billion, which was completed on February 27, 2026, and includes plans to separate early-stage precision cardiology programs into a new public company.
- Avidity's partnership with Novartis enhances its late-stage neuroscience pipeline, and the company aims to leverage Novartis's global reach to accelerate the development of its innovative RNA therapeutics.
- Ideal buyers for Avidity's solutions include pharmaceutical companies and healthcare providers focused on neuromuscular diseases, as Avidity's AOCs address previously untreatable conditions, making them a compelling option for advancing patient care.
Engineering is the largest group with 101 employees (about 29% of the company). Business Management and Healthcare each have 48 employees (roughly 14% each), followed by Operations with 37 (about 11%) and Finance and Administration with 36 (about 10%). Marketing and Product includes 20 team members (around 6%), Sales and Support has 13 (about 4%), Human Resources has 12 (about 3%), and Risk, Safety, Compliance has 11 (about 3%). Additional roles grouped as Other account for 28 employees (about 8%). This mix highlights a workforce spanning core R&D, corporate operations, and go-to-market support functions.
The largest concentration of employees is in San Diego, CA, with 173 people (about 49% of total headcount). Another 121 employees (about 34%) are based in other distributed locations not individually listed. Smaller employee groups are in San Francisco, CA (13); Boston, MA (11); Carlsbad, CA (9); Raleigh, NC (7); Philadelphia, PA (6); Seattle, WA (6); Los Angeles, CA (4); and Cambridge, MA (4). This footprint indicates a primary hub in San Diego complemented by teams across multiple U.S. cities and remote settings.
